7月11日A股投資避雷針︱三元生物:股東魯信資本擬減持不超3%股份;利民股份:實控人李明擬減持不超3%股份
德方納米股東吉學文擬減持不超3%股份;海波重科實控人張海波及其一致行動人擬減持合計不超2.00%股份;利民股份實控人李明擬減持不超3%股份;三元生物股東魯信資本擬減持不超3%股份;萬通發展股東北京復遠擬合計減持不超過3%股份;興森科技實際控制人擬減持不超過1.5021%股份;中創股份多名股東擬合計減持不超過3%股份;碧興物聯股東碧水源擬減持不超過1%股份

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.